Total Payments
$57,054
2024 Payments
$281.55
Companies
40
Transactions
328
Medicare Patients
2,144
Medicare Billing
$264,259
Payment Breakdown by Category
Other$40,095 (70.3%)
Consulting$6,860 (12.0%)
Food & Beverage$4,791 (8.4%)
Travel$4,615 (8.1%)
Education$691.92 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,095 | 19 | 70.3% |
| Consulting Fee | $6,860 | 3 | 12.0% |
| Food and Beverage | $4,791 | 281 | 8.4% |
| Travel and Lodging | $4,615 | 15 | 8.1% |
| Education | $691.92 | 10 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $53,134 | 67 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $782.55 | 54 | $0 (2024) |
| Genentech USA, Inc. | $510.99 | 47 | $0 (2024) |
| Janssen Biotech, Inc. | $318.86 | 23 | $0 (2018) |
| Merck Sharp & Dohme LLC | $218.62 | 18 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $208.94 | 18 | $0 (2024) |
| Lilly USA, LLC | $204.16 | 8 | $0 (2023) |
| Covis Pharma GmBH | $200.00 | 1 | $0 (2021) |
| EISAI INC. | $154.44 | 8 | $0 (2019) |
| PFIZER INC. | $147.16 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $281.55 | 15 | Novartis Pharmaceuticals Corporation ($47.50) |
| 2023 | $295.32 | 11 | Novartis Pharmaceuticals Corporation ($105.80) |
| 2022 | $11,642 | 22 | Incyte Corporation ($11,466) |
| 2021 | $8,362 | 11 | Incyte Corporation ($8,162) |
| 2020 | $7,925 | 8 | Incyte Corporation ($7,862) |
| 2019 | $17,073 | 22 | Incyte Corporation ($17,010) |
| 2018 | $9,601 | 92 | Incyte Corporation ($8,345) |
| 2017 | $1,872 | 147 | Novartis Pharmaceuticals Corporation ($355.78) |
All Payment Transactions
328 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Oncology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.17 | General |
| Category: Oncology | ||||||
| 12/13/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: CELLT | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Oncology | ||||||
| 12/02/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: BioOncology | ||||||
| 11/19/2024 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $26.77 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: Oncology | ||||||
| 07/09/2024 | Janssen Pharmaceuticals, Inc | RYBREVANT (Drug) | Education | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 12/15/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Oncology | ||||||
| 12/13/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $12.71 | General |
| Category: Oncology | ||||||
| 11/29/2023 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Oncology | ||||||
| 10/04/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: Oncology | ||||||
| 08/16/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Oncology | ||||||
| 07/25/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $32.69 | General |
| Category: Oncology | ||||||
| 03/22/2023 | Incyte Corporation | — | Education | Cash or cash equivalent | $85.95 | General |
| 03/13/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 358 | 544 | $116,124 | $38,510 |
| 2022 | 7 | 471 | 693 | $138,351 | $53,639 |
| 2021 | 10 | 612 | 1,025 | $180,058 | $91,360 |
| 2020 | 8 | 703 | 1,178 | $169,383 | $80,750 |
Total Patients
2,144
Total Services
3,440
Medicare Billing
$264,259
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 177 | 315 | $67,932 | $22,424 | 33.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 33 | 64 | $20,472 | $6,771 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 120 | 130 | $18,996 | $6,233 | 32.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $5,240 | $1,767 | 33.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 22 | $3,484 | $1,314 | 37.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 167 | 263 | $54,215 | $17,366 | 32.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2022 | 37 | 99 | $15,840 | $15,784 | 99.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 145 | 169 | $23,621 | $7,261 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 36 | 36 | $13,789 | $4,554 | 33.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 34 | 45 | $13,013 | $2,940 | 22.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 22 | 26 | $7,917 | $2,655 | 33.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 41 | $6,022 | $2,190 | 36.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 14 | 14 | $3,934 | $889.34 | 22.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 66 | 274 | $50,531 | $44,082 | 87.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 170 | 283 | $53,074 | $20,237 | 38.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 201 | 246 | $29,386 | $10,586 | 36.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 29 | 29 | $10,740 | $3,926 | 36.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 44 | $6,614 | $2,363 | 35.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 16 | $6,801 | $2,311 | 34.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 11 | 12 | $2,523 | $1,920 | 76.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 20 | 20 | $5,738 | $1,808 | 31.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 15 | $4,119 | $1,704 | 41.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 16 | $4,887 | $1,156 | 23.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 23 | $4,660 | $1,008 | 21.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 18 | 25 | $770.68 | $194.25 | 25.2% |
About Dr. Jamal Maatouk, MD
Dr. Jamal Maatouk, MD is a Medical Oncology healthcare provider based in Kingsport, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1205016060.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jamal Maatouk, MD has received a total of $57,054 in payments from pharmaceutical and medical device companies, with $281.55 received in 2024. These payments were reported across 328 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($40,095).
As a Medicare-enrolled provider, Maatouk has provided services to 2,144 Medicare beneficiaries, totaling 3,440 services with total Medicare billing of $264,259. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Kingsport, TN
- Active Since 11/09/2007
- Last Updated 11/15/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1205016060
Products in Payments
- JAKAFI (Drug) $52,791
- Avastin (Biological) $218.06
- IMBRUVICA (Drug) $209.82
- OPDIVO (Biological) $175.47
- KEYTRUDA (Biological) $161.49
- KISQALI (Drug) $156.29
- DARZALEX (Biological) $155.52
- JADENU (Drug) $141.36
- AFINITOR (Drug) $137.41
- MEKINIST (Drug) $136.68
- Perjeta (Biological) $114.97
- TASIGNA (Drug) $102.73
- Revlimid (Drug) $100.93
- FOUNDATIONONE (Device) $98.74
- TECENTRIQ (Biological) $93.15
- Lenvima (Drug) $80.09
- Halaven (Drug) $74.35
- Cabometyx (Drug) $69.72
- CYRAMZA (Drug) $58.11
- TUKYSA (Drug) $49.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.